Related Experiment Videos
Vaccination against hydatidosis using a defined recombinant antigen
M W Lightowlers1, S B Lawrence, C G Gauci
1Molecular Parasitology Laboratory, University of Melbourne, Werribee, Victoria, Australia.
Parasite Immunology
|September 1, 1996
Summary
A new vaccine targeting Echinococcus granulosus, the cause of hydatid disease, shows high protection rates in sheep. This EG95 antigen vaccine offers a promising strategy for controlling parasite transmission in animals and potentially humans.
Area of Science:
- Veterinary Parasitology
- Vaccinology
- Molecular Biology
Background:
- Echinococcus granulosus causes hydatid disease in humans and animals.
- Transmission occurs between dogs (definitive hosts) and various animal intermediate hosts.
- Current control methods for hydatidosis are insufficient, necessitating new strategies.
Purpose of the Study:
- To develop and evaluate a novel vaccine against Echinococcus granulosus.
- To assess the efficacy of a recombinant oncosphere antigen (EG95) in preventing hydatidosis.
Main Methods:
- Development of a vaccine using a cloned recombinant antigen (EG95) from the E. granulosus oncosphere.
- Vaccination of sheep with the EG95 antigen.
- Experimental challenge infection with E. granulosus eggs to assess protection.
Main Results:
- Sheep vaccinated with EG95 demonstrated high levels of protection (96-98%) against experimental hydatidosis.
- The vaccine effectively prevented the development of hydatid disease following challenge infection.
Conclusions:
- The EG95 vaccine is a valuable new tool for controlling Echinococcus granulosus transmission.
- This vaccine has significant potential for reducing hydatid disease in animal populations and possibly in humans.